Please enable JavaScript to continue using this application.

Compare $GYRE vs $IMMX | Chartloom

Compare

$GYRE vs $IMMX

Gyre Therapeutics Inc · Immix Biopharma Inc

GYRE

Gyre Therapeutics Inc

IMMX

Immix Biopharma Inc

Compare $GYRE vs $IMMX

Comparing Gyre Therapeutics Inc and Immix Biopharma Inc

GYREGyre Therapeutics Inc

IMMXImmix Biopharma Inc

GYREGyre Therapeutics Inc

Market cap

$643M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

16.8%

YTD performance

3.4%

52W performance

-3.6%

FCF yield

-2.6%

IMMXImmix Biopharma Inc

Market cap

$660M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

74.2%

52W performance

272.4%

FCF yield

-5.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GYRE

IMMX

Detailed metrics comparison

GYRE

Gyre Therapeutics Inc

IMMX

Immix Biopharma Inc

Market Cap

GYRE$643M

IMMX$660M

Enterprise Value

GYRE$600M

IMMX$435M

Price

GYRE$7.04

IMMX$9.46

P/E Ratio

GYREN/A

IMMXN/A

P/S Ratio

GYRE5.39x

IMMX0.00x

EV/Sales

GYRE5.03x

IMMX0.00x

EV/EBITDA

GYRE286.88x

IMMX0.00x

P/B Ratio

GYRE5.78x

IMMX3.03x

P/FCF Ratio

GYREN/A

IMMXN/A

EV/FCF

GYRE-35.74x

IMMX-11.12x

PEG Ratio

GYREN/A

IMMXN/A

Forward P/E (NTM)

GYREN/A

IMMXN/A

Forward P/S (NTM)

GYREN/A

IMMXN/A

Revenue (TTM)

GYRE$119M

IMMX$0

Revenue Growth (YoY)

GYRE16.8%

IMMXN/A

Forward Rev Growth

GYRE21.1%

IMMX452.1%

Gross Margin (TTM)

GYRE94.3%

IMMX0.0%

Operating Margin (TTM)

GYRE0.0%

IMMX0.0%

EBITDA Margin (TTM)

GYRE-8.5%

IMMX0.0%

Net Margin (TTM)

GYRE-15.5%

IMMX0.0%

FCF Margin (TTM)

GYRE-14.1%

IMMXN/A

Net Income (TTM)

GYRE$-18M

IMMX$-40M

FCF (TTM)

GYRE$-17M

IMMX$-39M

EPS (TTM)

GYRE-$0.18

IMMX-$0.63

ROE (TTM)

GYRE-1584.0%

IMMX-3844.0%

ROA (TTM)

GYRE-1014.0%

IMMX-3472.0%

ROIC (TTM)

GYRE-1584.0%

IMMX-3844.0%

Cash

GYRE$43M

IMMX$225M

Debt

GYRE$0

IMMX$0

Net Cash/Debt

GYRE$43M

IMMX$225M

Current Ratio (TTM)

GYRE4.26x

IMMX25.13x

Quick Ratio (TTM)

GYRE3.64x

IMMX24.98x

Debt/Equity (TTM)

GYRE0.00x

IMMX0.00x

Debt/Assets (TTM)

GYRE0.0%

IMMX0.0%

Interest Coverage (TTM)

GYREN/A

IMMXN/A

Net Debt/EBITDA (TTM)

GYRE0.00x

IMMX0.00x

Beta

GYRE2.46

IMMX0.22

52W Performance

GYRE-3.6%

IMMX272.4%

YTD Performance

GYRE3.4%

IMMX74.2%

% from 52W High

GYRE-25.3%

IMMX-37.4%

% from 52W Low

GYRE29.4%

IMMX309.5%

Asset Turnover (TTM)

GYRE0.70x

IMMX0.00x

FCF Yield (TTM)

GYRE-2.6%

IMMX-5.9%

Earnings Yield (TTM)

GYRE-2.9%

IMMX-6.0%

Dividend Yield (TTM)

GYREN/A

IMMXN/A

Rule of 40

GYRE2.8

IMMX0.0

EV/GP/RG

GYRE0.23

IMMXN/A

Ticker research

View GYRE research View IMMX research

Metric	GYRE Gyre Therapeutics Inc	IMMX Immix Biopharma Inc
Market & Valuation
Market Cap	$643M	$660M
Enterprise Value	$600M	$435M
Price	$7.04	$9.46
P/E Ratio	N/A	N/A
P/S Ratio	5.39x	0.00x
EV/Sales	5.03x	0.00x
EV/EBITDA	286.88x	0.00x
P/B Ratio	5.78x	3.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-35.74x	-11.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$119M	$0
Revenue Growth (YoY)	16.8%	N/A
Forward Rev Growth	21.1%	452.1%
Profitability
Gross Margin (TTM)	94.3%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-8.5%	0.0%
Net Margin (TTM)	-15.5%	0.0%
FCF Margin (TTM)	-14.1%	N/A
Net Income (TTM)	$-18M	$-40M
FCF (TTM)	$-17M	$-39M
EPS (TTM)	-$0.18	-$0.63
ROE (TTM)	-1584.0%	-3844.0%
ROA (TTM)	-1014.0%	-3472.0%
ROIC (TTM)	-1584.0%	-3844.0%
Financial Health
Cash	$43M	$225M
Debt	$0	$0
Net Cash/Debt	$43M	$225M
Current Ratio (TTM)	4.26x	25.13x
Quick Ratio (TTM)	3.64x	24.98x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.46	0.22
52W Performance	-3.6%	272.4%
YTD Performance	3.4%	74.2%
% from 52W High	-25.3%	-37.4%
% from 52W Low	29.4%	309.5%
Efficiency & Yields
Asset Turnover (TTM)	0.70x	0.00x
FCF Yield (TTM)	-2.6%	-5.9%
Earnings Yield (TTM)	-2.9%	-6.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	2.8	0.0
EV/GP/RG	0.23	N/A
Ticker research	View GYRE research	View IMMX research

Valuation

P/S Ratio

IMMX

0.00x

GYRE

5.39x

EV/FCF

GYRE

-35.74x

IMMX

-11.12x

Growth & revenue

Revenue Growth TTM

GYRE

16.8%

Forward Revenue Growth

IMMX

452.1%

GYRE

21.1%

Profitability & performance

Gross Margin

GYRE

94.3%

IMMX

0.0%

ROE

GYRE

-1584.0%

IMMX

-3844.0%

FCF Yield %

GYRE

-2.6%

IMMX

-5.9%

52-Week Performance

IMMX

272.4%

GYRE

-3.6%

Detailed metrics comparison

GYRE

Gyre Therapeutics Inc

IMMX

Immix Biopharma Inc

Market Cap

GYRE$643M

IMMX$660M

Enterprise Value

GYRE$600M

IMMX$435M

Price

GYRE$7.04

IMMX$9.46

P/E Ratio

GYREN/A

IMMXN/A

P/S Ratio

GYRE5.39x

IMMX0.00x

EV/Sales

GYRE5.03x

IMMX0.00x

EV/EBITDA

GYRE286.88x

IMMX0.00x

P/B Ratio

GYRE5.78x

IMMX3.03x

P/FCF Ratio

GYREN/A

IMMXN/A

EV/FCF

GYRE-35.74x

IMMX-11.12x

PEG Ratio

GYREN/A

IMMXN/A

Forward P/E (NTM)

GYREN/A

IMMXN/A

Forward P/S (NTM)

GYREN/A

IMMXN/A

Revenue (TTM)

GYRE$119M

IMMX$0

Revenue Growth (YoY)

GYRE16.8%

IMMXN/A

Forward Rev Growth

GYRE21.1%

IMMX452.1%

Gross Margin (TTM)

GYRE94.3%

IMMX0.0%

Operating Margin (TTM)

GYRE0.0%

IMMX0.0%

EBITDA Margin (TTM)

GYRE-8.5%

IMMX0.0%

Net Margin (TTM)

GYRE-15.5%

IMMX0.0%

FCF Margin (TTM)

GYRE-14.1%

IMMXN/A

Net Income (TTM)

GYRE$-18M

IMMX$-40M

FCF (TTM)

GYRE$-17M

IMMX$-39M

EPS (TTM)

GYRE-$0.18

IMMX-$0.63

ROE (TTM)

GYRE-1584.0%

IMMX-3844.0%

ROA (TTM)

GYRE-1014.0%

IMMX-3472.0%

ROIC (TTM)

GYRE-1584.0%

IMMX-3844.0%

Cash

GYRE$43M

IMMX$225M

Debt

GYRE$0

IMMX$0

Net Cash/Debt

GYRE$43M

IMMX$225M

Current Ratio (TTM)

GYRE4.26x

IMMX25.13x

Quick Ratio (TTM)

GYRE3.64x

IMMX24.98x

Debt/Equity (TTM)

GYRE0.00x

IMMX0.00x

Debt/Assets (TTM)

GYRE0.0%

IMMX0.0%

Interest Coverage (TTM)

GYREN/A

IMMXN/A

Net Debt/EBITDA (TTM)

GYRE0.00x

IMMX0.00x

Beta

GYRE2.46

IMMX0.22

52W Performance

GYRE-3.6%

IMMX272.4%

YTD Performance

GYRE3.4%

IMMX74.2%

% from 52W High

GYRE-25.3%

IMMX-37.4%

% from 52W Low

GYRE29.4%

IMMX309.5%

Asset Turnover (TTM)

GYRE0.70x

IMMX0.00x

FCF Yield (TTM)

GYRE-2.6%

IMMX-5.9%

Earnings Yield (TTM)

GYRE-2.9%

IMMX-6.0%

Dividend Yield (TTM)

GYREN/A

IMMXN/A

Rule of 40

GYRE2.8

IMMX0.0

EV/GP/RG

GYRE0.23

IMMXN/A

Ticker research

View GYRE research View IMMX research

Metric	GYRE Gyre Therapeutics Inc	IMMX Immix Biopharma Inc
Market & Valuation
Market Cap	$643M	$660M
Enterprise Value	$600M	$435M
Price	$7.04	$9.46
P/E Ratio	N/A	N/A
P/S Ratio	5.39x	0.00x
EV/Sales	5.03x	0.00x
EV/EBITDA	286.88x	0.00x
P/B Ratio	5.78x	3.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-35.74x	-11.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$119M	$0
Revenue Growth (YoY)	16.8%	N/A
Forward Rev Growth	21.1%	452.1%
Profitability
Gross Margin (TTM)	94.3%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-8.5%	0.0%
Net Margin (TTM)	-15.5%	0.0%
FCF Margin (TTM)	-14.1%	N/A
Net Income (TTM)	$-18M	$-40M
FCF (TTM)	$-17M	$-39M
EPS (TTM)	-$0.18	-$0.63
ROE (TTM)	-1584.0%	-3844.0%
ROA (TTM)	-1014.0%	-3472.0%
ROIC (TTM)	-1584.0%	-3844.0%
Financial Health
Cash	$43M	$225M
Debt	$0	$0
Net Cash/Debt	$43M	$225M
Current Ratio (TTM)	4.26x	25.13x
Quick Ratio (TTM)	3.64x	24.98x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.46	0.22
52W Performance	-3.6%	272.4%
YTD Performance	3.4%	74.2%
% from 52W High	-25.3%	-37.4%
% from 52W Low	29.4%	309.5%
Efficiency & Yields
Asset Turnover (TTM)	0.70x	0.00x
FCF Yield (TTM)	-2.6%	-5.9%
Earnings Yield (TTM)	-2.9%	-6.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	2.8	0.0
EV/GP/RG	0.23	N/A
Ticker research	View GYRE research	View IMMX research